Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.63 |
| ▸ | MAOB | P27338 | 4/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.63 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252967 | 1.00 | KDM1A (0.63) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL4265573 | 1.00 | KDM1A (0.63) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL4608247 | 0.81 | KDM1A (0.39) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL14804306 | 0.80 | KDM1A (0.56) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL26318046 | 0.80 | KDM1A (0.56) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL2141187 | 0.79 | HTR3A (0.46) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL1645757 | 0.79 | KDM1A (0.63) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL7898071 | 0.79 | KDM1A (0.63) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL3717970 | 0.79 | KDM1A (0.63) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL4260479 | 0.79 | GRIA4 (0.45) | KDM1AMAOBKCNH2RCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4666533-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| EP-1246797-B1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2008524279-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | claimed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | claimed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | claimed |
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1246797-B1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | KDM1A 1623/4885MAOB 3713/4885KCNH2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.